Structure Therapeutics American Stock Alpha and Beta Analysis
| GPCR Stock | 34.01 0.60 1.80% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Structure Therapeutics American. It also helps investors analyze the systematic and unsystematic risks associated with investing in Structure Therapeutics over a specified time horizon. Remember, high Structure Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Structure Therapeutics' market risk premium analysis include:
Beta 0.69 | Alpha (0.25) | Risk 4.22 | Sharpe Ratio (0.03) | Expected Return (0.14) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Structure |
Structure Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Structure Therapeutics market risk premium is the additional return an investor will receive from holding Structure Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Structure Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Structure Therapeutics' performance over market.| α | -0.25 | β | 0.69 |
Structure Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Structure Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Structure Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Structure Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Structure Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Structure Therapeutics shares will generate the highest return on investment. By understating and applying Structure Therapeutics stock market price indicators, traders can identify Structure Therapeutics position entry and exit signals to maximize returns.
Structure Therapeutics Return and Market Media
The median price of Structure Therapeutics for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 38.82 with a coefficient of variation of 7.47. The daily time series for the period is distributed with a sample standard deviation of 2.89, arithmetic mean of 38.68, and mean deviation of 2.14. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 525 shares by Fmr Llc of Structure Therapeutics subject to Rule 16b-3 | 09/13/2024 |
2 | Structure Therapeutics Announces Key Leadership Appointments to Accelerate Development | 09/18/2024 |
3 | Acquisition by Hall Ashley of 82890 shares of Structure Therapeutics at 12.75 subject to Rule 16b-3 | 09/20/2024 |
4 | Morgan Stanley starts Structure Therapeutics at overweight | 09/23/2024 |
5 | Structure Therapeutics Receives New Coverage from Analysts at Morgan Stanley | 09/27/2024 |
6 | Structure Therapeutics Inc. Receives 88.43 Consensus PT from Brokerages | 10/08/2024 |
7 | Structure Therapeutics Innovating Oral Therapies for Obesity and Diabetes | 10/16/2024 |
8 | Wellington Management Group LLPs Strategic Acquisition in Structure Therapeutics Inc | 11/08/2024 |
9 | Capital Research Global Investors Expands Stake in Structure Therapeutics Inc | 11/13/2024 |
10 | Structure Therapeutics to Participate in the Jefferies London Healthcare Conference | 11/15/2024 |
11 | Companies Like Structure Therapeutics Are In A Position To Invest In Growth | 11/25/2024 |
About Structure Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Structure or other stocks. Alpha measures the amount that position in Structure Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 12.62 | 7.16 | 19.14 | 10.31 | Net Debt To EBITDA | 0.002782 | 1.73 | 1.21 | 1.27 |
Structure Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Structure Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Structure Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Structure Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Structure Therapeutics. Please utilize our Beneish M Score to check the likelihood of Structure Therapeutics' management manipulating its earnings.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Structure Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.